BSE Live
Feb 17, 10:19Prev. Close
857.35
Open Price
857.25
Bid Price (Qty.)
867.30 (4)
Offer Price (Qty.)
868.00 (6)
NSE Live
Feb 17, 10:19Prev. Close
857.85
Open Price
860.00
Bid Price (Qty.)
867.85 (6)
Offer Price (Qty.)
868.30 (1)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Mar 15 | Mar 14 | Dec 12 | Dec 11 | Dec 10 | |
| 12 mths | 15 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 59.62 | 59.57 | 58.80 | 58.38 | 57.75 | |
| Total Share Capital | 59.62 | 59.57 | 58.80 | 58.38 | 57.75 | |
| Reserves and Surplus | 1,085.31 | 947.26 | 1,967.44 | 1,313.10 | 1,222.95 | |
| Total Reserves and Surplus | 1,085.31 | 947.26 | 1,967.44 | 1,313.10 | 1,222.95 | |
| Total Shareholders Funds | 1,144.92 | 1,006.83 | 2,026.24 | 1,371.48 | 1,282.78 | |
| Minority Interest | 18.71 | 75.67 | 71.85 | 46.46 | 272.47 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 267.39 | 42.00 | 731.15 | 1,054.31 | 1,390.88 | |
| Deferred Tax Liabilities [Net] | 0.00 | 4.39 | 28.74 | 9.35 | 4.64 | |
| Other Long Term Liabilities | 17.76 | 10.35 | 85.01 | 24.75 | 0.00 | |
| Long Term Provisions | 17.39 | 16.56 | 57.25 | 66.19 | 0.00 | |
| Total Non-Current Liabilities | 302.54 | 73.31 | 902.16 | 1,154.60 | 1,395.51 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 203.03 | 224.56 | 599.90 | 684.65 | 618.96 | |
| Trade Payables | 234.41 | 267.86 | 463.08 | 585.04 | 419.85 | |
| Other Current Liabilities | 502.47 | 357.58 | 651.66 | 1,369.80 | 305.00 | |
| Short Term Provisions | 80.03 | 93.22 | 82.66 | 152.24 | 198.80 | |
| Total Current Liabilities | 1,019.94 | 943.22 | 1,797.29 | 2,791.73 | 1,542.61 | |
| Total Capital And Liabilities | 2,486.11 | 2,099.02 | 4,797.54 | 5,364.26 | 4,493.38 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 435.58 | 374.13 | 992.35 | 955.36 | 597.19 | |
| Intangible Assets | 128.94 | 77.01 | 334.06 | 249.68 | 1,731.08 | |
| Capital Work-In-Progress | 145.59 | 64.19 | 63.94 | 17.49 | 191.46 | |
| Fixed Assets | 735.69 | 550.60 | 1,567.85 | 1,490.07 | 2,519.72 | |
| Non-Current Investments | 68.76 | 41.80 | 0.00 | 0.00 | 1.76 | |
| Deferred Tax Assets [Net] | 5.39 | 2.74 | 1.56 | 22.03 | 1.58 | |
| Long Term Loans And Advances | 108.73 | 91.54 | 125.71 | 238.66 | 0.00 | |
| Other Non-Current Assets | 1.27 | 0.31 | 1.17 | 5.63 | 9.92 | |
| Total Non-Current Assets | 1,056.67 | 790.39 | 3,386.61 | 3,738.99 | 2,532.98 | |
| CURRENT ASSETS | ||||||
| Current Investments | 561.29 | 401.24 | 0.06 | 0.00 | 0.00 | |
| Inventories | 207.68 | 175.99 | 442.33 | 479.93 | 312.00 | |
| Trade Receivables | 389.96 | 364.00 | 483.23 | 538.44 | 424.96 | |
| Cash And Cash Equivalents | 146.89 | 231.15 | 165.74 | 259.73 | 339.45 | |
| Short Term Loans And Advances | 112.58 | 122.68 | 133.53 | 178.35 | 884.00 | |
| OtherCurrentAssets | 11.06 | 13.59 | 186.04 | 168.83 | 0.00 | |
| Total Current Assets | 1,429.45 | 1,308.63 | 1,410.94 | 1,625.27 | 1,960.40 | |
| Total Assets | 2,486.11 | 2,099.02 | 4,797.54 | 5,364.26 | 4,493.38 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 3,878.98 | 4,024.52 | 214.07 | 285.16 | 52.98 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 68.76 | 41.80 | 0.00 | 0.00 | 1.76 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 561.29 | 401.24 | 0.06 | 0.00 | 0.00 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016